29 February 2024
ValiRx PLC ("ValiRx" or the
"Company")
Proposed Appointment of Non-Executive
Director
London, UK - ValiRx Plc (AIM: VAL), a life
science company focusing on early-stage cancer therapeutics and
women's health is pleased to announce that, subject to normal
regulatory due diligence, it intends to appoint Martin Gouldstone
as a Non-Executive Director of the Company.
Martin is currently CEO of Oncimmune Holdings
plc and has 30 years of corporate finance and business development
experience in contract research organisations, healthcare and
pharmaceutical sectors. Previously, Martin was a Global Senior Vice
President of Business Development at Owkin, Inc., where he managed
the commercial teams in the USA and Europe and led new strategic
research partnerships. More recently, Martin was Chief Business
Officer at Sensyne Health; Global Senior Vice President and Head of
Capital Solutions for Syneos Health; Chief Business Officer at
BenevolentAI.
Martin was previously a Partner at Results
Healthcare (now CG Results Healthcare), where he co-led the
healthcare practice; Head of Lifesciences in the UK for BDO,
M&A Lead for Europe at Quintiles (now IQVIA Inc), and held
business development and licensing lead roles at Confirmant Ltd and
Sareum Holdings PLC. Martin has extensive experience buying and
selling deals across Europe and the US, and in negotiating
multi-year research partnerships.
Currently, Martin is also a Non-Executive
Director of hVIVO plc (formerly Open Orphan plc) and sits on the
Board of Trustees of Orthopaedic Research UK. Martin holds a BSc in
Genetics and has completed a range of postgraduate management
courses.
Dr Kevin Cox,
Chair of ValiRx PLC, commented "Martin will be
an invaluable addition to the Board of ValiRx and his extensive
experience in our sector will provide help and advice across all
areas of the business. I am delighted that he shares our vision for
ValiRx and look forward to working with him."
Dr Suzy Dilly,
CEO of ValiRx PLC commented "I'm delighted to
be working with Martin, drawing on his breadth of commercial
experience in business growth and deal making, bringing support to
both our licencing activities and helping in the growth of Inaphaea
Biolabs."
The information contained within this
announcement is deemed by the Company to constitute inside
information as stipulated under the Market Abuse Regulations (EU)
No. 596/2014 as it forms part of UK Domestic Law by virtue of the
European Union (Withdrawal) Act 2018 ("UK MAR"). The Directors of
the Company take responsibility for this announcement.
For more information, please
contact:
ValiRx
plc
Dr Suzanne Dilly, CEO
|
Tel: +44 (0)
2476 796496
www.valirx.com
Suzanne.Dilly@valirx.com
|
V Formation
(Public Relations)
Lucy Wharton - Senior PR Executive
Sue Carr - Director
|
+44 (0) 115
787 0206
www.vformation.biz
lucy@vformation.biz
sue@vformation.biz
|
Cairn
Financial Advisers LLP (Nominated Adviser)
Liam Murray/Ludovico Lazzaretti
|
Tel: +44 (0)
20 7213 0880
|
Shard Capital
Partners LLP (Sole Broker)
Damon Heath
|
Tel: +44 (0)
20 7186 9000
|
Notes for
Editors
About
ValiRx
UValiRx is a life science company focused on
early-stage cancer therapeutics and women's health, accelerating
the translation of innovative science into impactful medicines to
improve patient lives.
ValiRx provides the scientific, financial, and
commercial framework for enabling rapid translation of innovative
science into clinical development.
Using its extensive and proven experience in
research and drug development, the team at ValiRx selects and
incubates promising novel drug candidates and guides them through
an optimised process of development, from pre-clinical studies to
clinic and investor-ready assets.
ValiRx connects diverse disciplines across
scientific, technical, and commercial domains, with the aim of
achieving a more streamlined, less costly, drug development
process. The team works closely with carefully selected
collaborators and leverages the combined expertise required for
science to advance.
Lead candidates from ValiRx's portfolio are
outlicensed or partnered with investors through ValiRx subsidiary
companies for further clinical development and
commercialisation.
ValiRx listed on the AIM Market of the London
Stock Exchange in October 2006 and trades under the ticker symbol:
VAL.
For further information, visit:
www.valirx.com
Cautionary
statement
Certain statements made in this announcement
are forward-looking statements. Such statements are based on
current expectations and assumptions and are subject to a number of
risks and uncertainties that could cause actual events or results
to differ materially from any expected future events or results
expressed or implied in these forward-looking statements. Persons
receiving this announcement should not place undue reliance on
forward-looking statements. Unless otherwise required by applicable
law, regulation or accounting standard, the Company does not
undertake to update or revise any forward-looking statements,
whether as a result of new information, future developments or
otherwise.